Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 10/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21180017 | 0.87 | CYP17A1 (0.59) | CYP17A1NR3C1PGRNR3C2KDM1A | |
| SCHEMBL3378288 | 0.86 | KIF11 (0.59) | CYP17A1NR3C1PGRNR3C2KDM1A | |
| SCHEMBL29788285 | 0.85 | CYP17A1 (0.60) | CYP17A1NR3C1PGRNR3C2KDM1A | |
| SCHEMBL3374264 | 0.85 | KIF11 (0.62) | CYP17A1KDM1APLAU | |
| SCHEMBL23675899 | 0.83 | CYP17A1 (0.57) | CYP17A1NR3C1PGRNR3C2KDM1A | |
| SCHEMBL3376946 | 0.83 | CYP17A1 (0.51) | CYP17A1NR3C1KDM1APLAUKIT | |
| SCHEMBL3378630 | 0.83 | KIF11 (0.67) | CYP17A1KDM1APLAU | |
| SCHEMBL2038889 | 0.82 | CYP17A1 (0.51) | CYP17A1NR3C1PGRNR3C2KDM1A | |
| SCHEMBL3379840 | 0.81 | TNIK (0.54) | CYP17A1NR3C1KIT | |
| SCHEMBL6161943 | 0.80 | KCNH2 (0.43) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | CYP17A1 3984/4885NR3C1 2869/4885PGR 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.